CJC-1295 (no-DAC) + Ipamorelin Blend Dosage and Protocols
CJC-1295 (no-DAC) + Ipamorelin Blend dosage protocols reported in published research, plus reconstitution and storage.
Dosage Protocols
No FDA-approved dosing guidelines exist for CJC-1295. The following protocols are derived from clinical research and community reports.
CJC-1295 without DAC (Mod GRF 1-29)
Conservative starting dose: 50–100 mcg per injection Frequency: 1–2 times daily (bedtime dose is considered most important) Timing: Often administered before bed to coincide with natural GH release, and/or upon waking Cycle length: 8–12 weeks, followed by 4 weeks off
CJC-1295 with DAC
Starting dose: 300 mcg per injection twice weekly Maintenance dose: 300–600 mcg once or twice weekly
How to Use / Administration
CJC-1295 is administered via subcutaneous injection , typically into the abdominal fat, thigh, or upper arm. Draw the appropriate dose using an insulin syringe (typically 29–31 gauge) Clean the injection site with an alcohol swab Pinch the skin and insert the needle at a 45-degree angle Rotate injection sites to prevent lipodystrophy For CJC-1295 without DAC, most protocols involve once or twice daily injections. The bedtime dose is considered the most important, as it coincides with the body's natural nocturnal GH surge. A morning dose can be added for those seeking additional effect. For CJC-1295 with DAC, once or twice weekly injections are sufficient due to the extended half-life. Consistency in timing (e.g., every Monday and Thursday) helps maintain stable blood levels.
Reconstitution, Storage & Prep
CJC-1295 is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use. Allow the peptide vial to reach room temperature Using bacteriostatic water (preferred) or sterile water, slowly inject the diluent down the inside wall of the vial, never directly onto the powder Gently swirl the vial until the powder is fully dissolved; do not shake vigorously For a 2 mg vial, adding 2 mL of bacteriostatic water creates a concentration of 1 mg/mL (1000 mcg/mL), making dosing calculations straightforward Unreconstituted powder: Store in a cool, dry place; refrigeration extends shelf life to 24+ months Reconstituted solution: Must be refrigerated at 2–8°C (36–46°F) With bacteriostatic water: Stable for approximately 4–6 weeks refrigerated
Reported protocol doses
Doses shown are those reported in published research, not a recommendation.
References
- Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. · Hoffmann P, Feige JJ, Alfaidy N · 2006
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. · Sackmann-Sala L, Ding J, Frohman LA et al. · 2009
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. · Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH · 1998
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. · Beck DE, Sweeney WB, McCarter MD et al. · 2014
- Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem - NIH
- Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005. · Chung S, Son GH, Park SH, Park E, Lee KH, Geum D, Kim K · 2005